D. Boral Capital Served as Co-Manager to ImmunityBio, Inc. (Nasdaq: IBRX) in connection with its $100.0 Million Underwritten Public Offering

Core Viewpoint - ImmunityBio, Inc. has announced a public offering of 33,333,334 shares of common stock at a price of $3.00 per share, aiming to raise approximately $100 million in gross proceeds [1][3]. Group 1: Offering Details - The underwriters have a 30-day option to purchase an additional 5,000,000 shares at the public offering price [1]. - The offering is expected to close on or about December 12, 2024, subject to customary closing conditions [1]. - Jefferies and Piper Sandler are acting as joint book-running managers for the offering, with BTIG and H.C. Wainwright & Co. as co-lead managers [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance the commercialization of ANKTIVA® for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and to fund trials in BCG-naïve NMIBC and non-small cell lung cancer (NSCLC) [3]. - Additional uses include further research and development, working capital needs, and other general corporate purposes [3]. Group 3: Company Overview - ImmunityBio is a biotechnology company focused on developing immunotherapies that enhance the natural immune system to combat cancers and infectious diseases [5]. - ANKTIVA® is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS, designed to activate natural killer cells and T cells for a prolonged immune response [5].